Citations

1. Levy D, et al. (2002). Long-term trends in the incidence of and survival with heart failure. New England Journal of Medicine, 347(18): 1397–1443.

2. American College of Cardiology and American Heart Association (2005). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Summary article. Available online: http://content.onlinejacc.org/cgi/content/full/46/6/1116.

3. Nicola PJ, et al. (2005). The risk of congestive heart failure in rheumatoid arthritis: A population-based study over 46 years. Arthritis and Rheumatism, 52(2): 412–420.

4. McKelvie R (2005). Heart failure. Clinical Evidence (13): 115–138.

5. Pitt B, et al. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine, 341(10): 709–717.

6. Cleland JGF, et al. (2005). The effect of cardiac resynchronization on morbidity and mortality in heart failure. New England Journal of Medicine, 352(15): 1539–1549.

7. Abraham WT, et al. (2002). Cardiac resynchronization in chronic heart failure. New England Journal of Medicine, 346(24): 1845–1858.

8. Kadish A, et al. (2004). Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. New England Journal of Medicine, 350(21): 2151–2158.

9. Bristow MR, et al. (2004). Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. New England Journal of Medicine, 350(21): 2140–2150.

10. Yusef S, et al. (2002). A lifetime of prevention: The case of heart failure. Circulation, 106(24): 2997–2998.

11. Abramson JL, et al. (2001). Moderate alcohol consumption and risk of heart failure among older persons. JAMA, 285(15): 1971–1977.

12. Taylor AL, et al. (2004). Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. New England Journal of Medicine, 351(20): 2049–2057.

13. American College of Cardiology and American Heart Association (2002). ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices. Summary article. Report of the ACC/AHA Task Force on Practice Guidelines. Available online: http://circ.ahajournals.org/cgi/content/full/106/16/2145

14. U.S. Food and Drug Administration (2002). FDA approves new type of defibrillator. FDA Talk Paper T02-22. Available online: http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01149.html.

15. Watson PS, et al. (1999). Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. Journal of the American College of Cardiology, 33(6): 1549–1552.

16. Morelli V, Zoorob RJ (2000). Alternative therapies: Part II. Congestive heart failure and hypercholesterolemia. American Family Physician, 62(6): 1325–1330.

Other Works Consulted

• American Heart Association and American College of Cardiology (2006). AHA/ACC Guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation, 113(19): 2363–2372. [Erratum in Circulation, 113(22): 847.]

• Drugs for treatment of heart failure (2006). Treatment Guidelines from the Medical Letter, 4(41): 1–4.